Literature DB >> 23038225

Mortality of patients with hematological malignancy after admission to the intensive care unit.

Sophia Horster1, H Joachim Stemmler, Philipp C Mandel, Alexander Mück, Johanna Tischer, Andreas Hausmann, Klaus G Parhofer, Sandra Geiger.   

Abstract

BACKGROUND: The admission of patients with malignancies to an intensive care unit (ICU) still remains a matter of substantial controversy. The identification of factors that potentially influence the patient outcome can help ICU professionals make appropriate decisions. PATIENTS AND METHODS: 90 adult patients with hematological malignancy (leukemia 47.8%, high-grade lymphoma 50%) admitted to the ICU were analyzed retrospectively in this single-center study considering numerous variables with regard to their influence on ICU and day-100 mortality.
RESULTS: The median simplified acute physiology score (SAPS) II at ICU admission was 55 (ICU survivors 47 vs. 60.5 for non-survivors). The overall ICU mortality rate was 45.6%. With multivariate regression analysis, patients admitted with sepsis and acute respiratory failure had a significantly increased ICU mortality (sepsis odds ratio (OR) 9.12, 95% confidence interval (CI) 1.1- 99.7, p = 0.04; respiratory failure OR 13.72, 95% CI 1.39-136.15, p = 0.025). Additional factors associated with an increased mortality were: high doses of catecholamines (ICU: OR 7.37, p = 0.005; day 100: hazard ratio (HR) 2.96, p < 0.0001), renal replacement therapy (day 100: HR 1.93, p = 0.026), and high SAPS II (ICU: HR 1.05, p = 0.038; day 100: HR 1.2, p = 0.027).
CONCLUSION: The decision for or against ICU admission of patients with hematological diseases should become increasingly independent of the underlying malignant disease.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23038225     DOI: 10.1159/000342672

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  6 in total

1.  One-year mortality among non-surgical patients with hematological malignancies admitted to the intensive care unit: a Danish nationwide population-based cohort study.

Authors:  Peter H Asdahl; Steffen Christensen; Anders Kjærsgaard; Christian F Christiansen; Peter Kamper
Journal:  Intensive Care Med       Date:  2020-01-29       Impact factor: 17.440

2.  Prognostic factors in critically ill patients with hematological malignancy admitted to the general intensive care unit: a single-center experience in Japan.

Authors:  Hiromasa Irie; Takanao Otake; Keiko Kawai; Masaaki Hino; Ayano Namazu; Yasutaka Shinjo; Shigeki Yamashita
Journal:  J Anesth       Date:  2017-08-01       Impact factor: 2.078

3.  Predictors of mortality among patients with acute leukemias admitted to an intensive care unit specialized in patients with hematological disease at a Brazilian hospital.

Authors:  Lorena Costa Corrêa; Dahra Teles; Odin Barbosa da Silva; Gustavo Henriques Trindade-Filho; Paula Loureiro; Maria do Socorro Mendonça Cavalcati
Journal:  Hematol Transfus Cell Ther       Date:  2019-04-26

4.  Predictors of intensive care unit admission in patients with hematologic malignancy.

Authors:  Abi Vijenthira; Nicholas Chiu; Daniel Jacobson; Zoey Freedman; Matthew C Cheung; Shannon Goddard; Robert Fowler; Rena Buckstein
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

5.  Outcomes of Patients with Malignancy Admitted to the Intensive Care Units: A Prospective Study.

Authors:  Hazem I Assi; Nour Abdul Halim; Ibrahim Alameh; Jessica Khoury; Vicky Nahra; Fares Sukhon; Maya Charafeddine; Clara El Nakib; Nour Moukalled; Maroun Bou Zerdan; Pierre Bou Khalil
Journal:  Crit Care Res Pract       Date:  2021-09-01

Review 6.  A Systematic Review and Meta-Analysis Evaluating Geographical Variation in Outcomes of Cancer Patients Treated in ICUs.

Authors:  Lama H Nazer; Maria A Lopez-Olivo; Anne Rain Brown; John A Cuenca; Michael Sirimaturos; Khader Habash; Nada AlQadheeb; Heather May; Victoria Milano; Amy Taylor; Joseph L Nates
Journal:  Crit Care Explor       Date:  2022-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.